Overview / Abstract: |
Credit Available Physicians — maximum of 0.25 AMA PRA Category 1 Credit(s)™ Target Audience This activity is primarily intended for endocrinologists, primary care physicians, and nurses who care for patients with T2D. Program Overview The goal of this activity is to improve learners’ competence and performance in SGLT2 inhibitor treatment decisions for patients with T2D with and without related comorbidities. Learning Objectives Upon completion of this activity, participants should be able to: Apply recommendations from the latest ADA and AACE diabetes management guidelines regarding use of SGLT2-I drugs in patients with varying degrees of CV and/or renal risk |
Expiration |
Dec 08, 2021 |
Discipline(s) |
Nursing CNE, Physician CME |
Format |
Online |
Credits / Hours |
0.25 AMA PRA Category 1 Credit(s)™ |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Faculty FACULTY_NAME FACULTY_NAME FACULTY_NAME FACULTY_NAME FACULTY_NAME |
Sponsors / Supporters / Grant Providers |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Keywords / Search Terms |
Relias LLC Relias LLC., T2D ,Free CME Free CE CME |